Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Wed, 06.07.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of a validated manufacturing process as well as [ … ]
Wed, 06.07.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 6 July 2022. Eckert & Ziegler (ISIN DE0005659700, SDAX) has signed an agreement with the U.S. pharmaceutical company Ratio Therapeutics Inc. for the joint development and manufacture of innovative radiopharmaceutical products based on Lu-177 and Ac-225. The agreement covers the development of a validated manufacturing process as well as [ … ]
Tue, 05.07.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 5 July 2022. Due to slow consultation progress and a general worsening of the international business climate the Management Board of Eckert & Ziegler has concluded that the probability of an extraordinary profit from a sale or readjustments of assets, still within calendar year 2022 and in an amount of 14.3 mm EUR, has decreased to less [ … ]
Tue, 05.07.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 5 July 2022. Due to slow consultation progress and a general worsening of the international business climate the Management Board of Eckert & Ziegler has concluded that the probability of an extraordinary profit from a sale or readjustments of assets, still within calendar year 2022 and in an amount of 14.3 mm EUR, has decreased to less [ … ]
Thu, 12.05.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 12 May 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 13% to EUR 49.9 million in the first quarter of 2022. The net profit of EUR 6.7 million or EUR 0.32 per share was below the previous year's quarter. This earnings gap compared to the previous year is due to a one-off effect o [ … ]
Wed, 11.05.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 11 May 2022. Eckert & Ziegler AG (ISIN DE0005659700, TecDAX), a specialist in medical radioisotopes, has entered into a long-term cooperation agreement with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, UJF) to produce the alpha emitter Actinium-225. The agreement envisions Eckert & Ziegler to [ … ]
Fri, 08.04.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin / Nijmegen, 8 April 2022. Radboud University Medical Center (RUMC) in Nijmegen, one of the largest centres of excellence in the Netherlands for adrenal diseases, treated the first patient with primary aldosteronism with the Ga-68-based diagnostic PENTIXAFOR as part of the CASTUS study.
Developed by PentixaPharm, PENTIXAFOR is an innovative [ … ]
Wed, 06.04.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 6 April 2022. Based on preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) will achieve sales of around EUR 47 million (previous year: 44) and a net income of around EUR 6.5 million (previous year: 13.8) for the first quarter of 2022. The earnings gap compared to the previous year is explained by a one-off effect o [ … ]
Wed, 30.03.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 30 March 2022. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) achieved sales of EUR 180.4 million in fiscal year 2021 (previous year: EUR 176.1 million). The consolidated net income for the year reached a new record level of EUR 34.5 million (previous year: EUR 22.9 million) or EUR 1.67 per share (previous [ … ]
Thu, 24.03.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, March 24, 2022 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed fiscal year 2021 with sales of 180.4 million EUR (previous year: 176.1 million EUR) and net income of 34.5 EUR (previous year: 22.9 million EUR). Earnings per share amounted to EUR 1.67 (previous year: EUR 1.11). Based on these figures, the Executive Board and Super [ … ]